Wake Forest Baptist - Comprehensive Cancer Center
Atrium Health
Winston-Salem, NC
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Accepting patients
DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Phase 3
Accepting patients
ABBV-383
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
Linvoseltamab
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Learn more- Bispecific Antibody
- BCMA
- Phase 1
Accepting patients
Chemosensitivity Study
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity (Organoid)
Learn moreAccepting patients
Patient Registry: Undergoing Stem Cell Transplant
The Prospective Collection, Storage and Reporting of Data on Patients
Learn more- Patient Registry
- Observational Trial
Accepting patients
Isatuximab Combination Therapy
Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma
Learn more- Immunomodulatory Drug
- Phase 2
Accepting patients
IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Learn more- Natural Killer Cells (Allogeneic)
- Phase 1/2
Accepting patients
GEO-CM04S1 vs mRNA SARS-COV-2 Vaccine
A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies
Learn more- Vaccine
- COVID-19
- Randomization
- Phase 2
Accepting patients
Nivolumab Post Treatment with Ide-Cel
Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Response To Idecabtagene Vicleucel
Learn more- Checkpoint Inhibitor
- Monoclonal Antibody
- PD-1
- Phase 2
Accepting patients
ABBV-383
A Multicenter, Phase 1b, Open-label Study of ABBV-383 Administered Subcutaneously in Subjects With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 1